Hims & Hers Shares Rocket on Weight Loss Injections
$Hims & Hers Health (HIMS.US)$ has added GLP-1 weight-loss injections to its portfolio of products.
The injections will have the same active ingredient as $Novo-Nordisk A/S (NVO.US)$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
The injections will have the same active ingredient as $Novo-Nordisk A/S (NVO.US)$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, which is the active ingredient in $Eli Lilly and Co (LLY.US)$ ’s Mounjaro and Zepbound drugs.
The company began venturing into the weight-loss industry last December and expects to generate over $100 million from its weight-loss offerings by the end of 2025. Hims & Hers also offers weight-loss oral medication kits that start at $79 per month.
The company began venturing into the weight-loss industry last December and expects to generate over $100 million from its weight-loss offerings by the end of 2025. Hims & Hers also offers weight-loss oral medication kits that start at $79 per month.
The market for weight-loss drugs is sizable. Hims & Hers notes that 70% of American adults are either overweight or obese. GLP-1 can help alleviate this and reduce the risk of complications like diabetes and cardiovascular disease along the way.
This comes after the company reported first-quarter revenue growth of 46% to $278.2 million.
This comes after the company reported first-quarter revenue growth of 46% to $278.2 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
